MedTrace Logo

Named Patient Program for Mitomycin for Pyelocalyceal Solution

NCT05494411 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-02-28

No results posted yet for this study

Summary

This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.

Conditions

  • Urothelial Cancer of Renal Pelvis
  • Urothelial Carcinoma of the Renal Pelvis and Ureter
  • Urothelial Carcinoma Ureter
  • Urothelial Carcinoma Ureter Recurrent
  • Urothelial Carcinoma
  • Urothelial Carcinoma Recurrent

Interventions

DRUG

Mitomycin for pyelocalyceal solution

Sponsors & Collaborators

  • Tanner Pharma Group

    collaborator OTHER

  • UroGen Pharma Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494411 on ClinicalTrials.gov